Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

To the Editor: In the PACIFIC trial, Antonia et al. (Dec. 13 issue) 1 found a significant overall survival benefit from maintenance treatment with durvalumab after chemoradiotherapy for stage III non–small-cell lung cancer. This survival benefit was prominent in the programmed death ligand 1 (PD-L1)–positive subgroup of patients (PD-L1 expression ≥1%), but no survival benefit was evident in the PD-L1–negative subgroup (PD-L1 expression